NICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft guidance. Ultomiris is Alexion’s follow-up to ...

Alexion CEO Marc Dunoyer stated: “The approval of first-in-class, Factor D inhibitor Voydeya marks an important advancement in the treatment of PNH and builds on our leadership and commitment to ...

AG10 for ATTR cardiomyopathy and ALXN2040 or PNH patients with extravascular haemolysis (EVH). “Alexion has established itself as a leader in complement biology, bringing life-changing benefits ...

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well ...

Ultomiris and Soliris are also marketed by AstraZeneca for treating PNH and some other rare disease ... 2021 acquisition of rare disease drugmaker Alexion. The acquisition added Alexion’s ...

To guide them through an aHUS diagnosis and subsequent treatment, Alexion Pharmaceuticals has released an interactive storybook aimed at “demystifying” the disease for 6- to 10-year-olds ...

New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion ...